SUCCIPRO AIMS TO EXPLOIT THE SUCCINATE-METABOLIC-INFLAMMATORY AXIS TO CREATE NOVEL, FIRST-IN CLASS THERAPEUTICS FOR INFLAMMATORY AND METABOLIC DISEASES.
SUCCIPRO is a spin-off company from IISPV and URV which aims to exploit the succinate-metabolic-inflammatory axis to create novel, first-in class therapeutics for inflammatory and metabolic diseases
Carry out the preclinical and early clinical development of succinate-modulating therapies for inflammatory and metabolic diseases, particularly obesity, type 2 diabetes and Crohn’s disease.
Contribute to the long-term health of the people through science and provide effective solutions to people suffering from illnesses with a strong chronic inflammatory component by lowering succinate levels.
We are pioneers in the discovery and development of novel pharmaceuticals based on our unrivaled understanding of succinate biology and its role at the crossroad of inflammation and metabolism.
We are using our knowledge, expertise and unique propietary tools to generate a pipeline of pre-clinical candidates with a focus on inflammatory and metabolic diseases.
Succinate is elevated in many pathological situations with a metabolic and/or a inflammatory component. Building on the breakthrough science from DIAMET research team, we are currently developing drugs able to reduce succinate to improve metabolism and reduce inflammation.
We have a diversified pipeline of biological proprietary succinate-modulating compounds with different Target Product Profiles.
Our first asset is a first-in-class, gut- restricted, monitorable, succinate-modulating therapy able to decrease intestinal and systemic succinate, improve inflammmation and metabolism and prevent fibrosis that has Inflamamtory Bowel Disease as a Primary Indication.
Pharmacist holding a PhD in Biochemistry from the University of Barcelona and an MBA from the Barcelona Biotechnology with more than 10 years of expertise in preclinical research
Clinical coordinator of the DIAMET research group. Head of Endocrinology at the Joan XXIII University Hospital and full professor at the Universitat Rovira i Virgili.
Key Opinion Leader in succinate biology with more than 50 publications and an H-score of 18, Principal investigator of the DIAMET group
Spin-off company from Rovira Virgli University and Pere Virgili Research Health Institute. Support received from ACCIÓ (StartUp Capital Grant code ACE052/22/000049) and from the European Union through the WomenTechEU Program (code 101114086).
Funding from NEOTEC (SNEO-20231359), Torres Quevedo (2022 PTQ2022-012572 MCIN/AEI /10.13039/501100011033)
Carrer Dr. Mallafré Guasch, 4, 43007 Tarragona Spain